Literature DB >> 34674620

Toxicity and Surface Modification of Dendrimers: A Critical Review.

Rohini Kharwade1, Payal Badole1, Nilesh Mahajan1, Sachin More1.   

Abstract

Compared to other nano polymers, dendrimers have novel three-dimensional, synthetic hyperbranched, nano-polymeric structures. These supramolecular dendritic structures have a high degree of significant surface and core functionality in the transportation of drugs for targeted therapy, specifically in host-guest response, gene transfer therapy, and imaging of biological systems. However, there are conflicting shreds of evidence regarding biological safety and dendrimers toxicity due to their positive charge at the surface. It includes cytotoxicity, hemolytic toxicity, haematological toxicity, immunogenicity, and in vivo toxicity. Surface modification of the dendrimer group is one of the methods to resolve these issues. This review aimed at investigating different strategies that can reduce toxicity and improve the biocompatibility of different dendrimers. From that viewpoint, we broaden the structural and safe characteristics of the dendrimers in the biomedical and pharmaceutical fields. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Dendrimer; cationic charge; cytotoxicity; immunogenicity; improved biocompatibility; surface modification

Mesh:

Substances:

Year:  2022        PMID: 34674620     DOI: 10.2174/1567201818666211021160441

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  2 in total

Review 1.  Safety Challenges and Application Strategies for the Use of Dendrimers in Medicine.

Authors:  Xiang Li; Abid Naeem; Shanghua Xiao; Lei Hu; Jing Zhang; Qin Zheng
Journal:  Pharmaceutics       Date:  2022-06-17       Impact factor: 6.525

2.  A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant.

Authors:  Yi-Chung Chang; Chi-Fan Yang; Yi-Fen Chen; Chia-Chun Yang; Yuan-Lin Chou; Hung-Wen Chou; Tein-Yao Chang; Tai-Ling Chao; Shu-Chen Hsu; Si-Man Ieong; Ya-Min Tsai; Ping-Cheng Liu; Yuan-Fan Chin; Jun-Tung Fang; Han-Chieh Kao; Hsuan-Ying Lu; Jia-Yu Chang; Ren-Shiuan Weng; Qian-Wen Tu; Fang-Yu Chang; Kuo-Yen Huang; Tong-Young Lee; Sui-Yuan Chang; Pan-Chyr Yang
Journal:  EMBO Mol Med       Date:  2022-02-21       Impact factor: 12.137

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.